WCIO 2008 and Best of ASCO^®
June 22 - 25, 2008
Hyatt Regency Century Plaza
Los Angeles, CA

Back to Full Scientific Program

SUNDAY, June 22, 2008
1:30 pm – 3:30 pm		Concurrent ONCOLOGY SESSION I: BEST OF ASCO 1.  Welcome and Introductions - Mark Pegram, Masakatsu Toi   2.  Gastrointestinal Colorectal Cancers - Al Benson Randomized phase III study of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) Randomized phase III trial comparing infused 5-fluorouracil/folinic acid (LV5FU) versus LV5FU+irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC). (CPT-GMA-301) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials.   3.  Gastrointestinal Non-Colorectal Cancers - Jordan Berlin CONKO-001: Final Results of the randomized, prospective, multicenter phase 3 trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer (PC) A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907) A randomized, double blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201   4.  Genitourinary Cancers - William Figg RAD001 plus best supportive care (BSC) vs BSC plus placebo in patients with metastatic renal cell carcinoma (RCC), which has progressed on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-3 study Radiotherapy versus Carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomised trial (ISRCTN27163214) Abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, has significant and durable anti-tumor activity in both chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer (CRPC) Impact of Androgen Deprivation Therapy (ADT) on bone, cardiovascular, and endocrine outcomes: a propensity-matched analysis of 20,000 patients
4:00 pm – 5:30 pm		Concurrent ONCOLOGY SESSION II: BEST OF ASCO 1.  Breast Cancer - Local Regional Adjuvant Therapy – Peter Ravdin Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12 Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older. Results of CALGB/CTSU 49907 Vitamin D (Vit D) deficiency is common at breast cancer (BC) diagnosis and is associated with a significantly higher risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early stage breast cancer (EBC) Zoledronic Acid (ZA) preserves bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 79809   2.  Breast Cancer - Metastatic - Mark Pegram Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple negative (basal-like) breast cancer Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population based database and tissue microarray series   3.  Melanoma - Donald Morton Final results of the Sunbelt Melanoma Trial Sentinel lymph node biopsy (SLNB) improves survival among SEER patients with melanoma
MONDAY, June 23, 2008
1:30 PM – 3:30 PM		Concurrent ONCOLOGY SESSION III: BEST OF ASCO 1.  Lung Cancer - David Gandara S0124: A randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated extensive stage small cell lung cancer (E-SCLC) Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED-SCLC): final results of a randomised phase III trial Phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC): Interim results Randomized trial of standard dose to a higher dose prophylactic cranial irradiation (PCI) in limited-stage small cell cancer (SCLC) complete responders (CR): Primary end-point analysis (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212) FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC) A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study   2.  Patient and Survivor Care - Patricia Ganz A Phase III randomized, placebo-controlled, double-blind trial of a eugeroic agent in 642 cancer patients reporting fatigue during chemotherapy: A URCC CCOP Study Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer Cardiovascular disease in adult survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study (CCSS) Management recommendations for women at increased familial risk for breast cancer: Results of a prospective national multi-modality cohort study   3.  Gynecologic Cancers - Maurie Markman Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology AZD2281 (KU-0059436), a PARP (Poly ADP-ribose Polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a Phase I study
4:00 pm – 5:30 pm		Concurrent ONCOLOGY SESSION IV: BEST OF ASCO 1.  Lymphoma/Leukemia/Myeloma – TBD Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the Michelangelo, GITIL and IIL cooperative groups International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF) Azacitidine (AZA) extends overall survival in higher-risk myelodysplastic syndromes (MDS) without necessity for complete remission Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) Total therapy (TT) for myeloma (MM): 10% cure rate with TT1 suggested by >10yr continuous complete remission (CCR): Bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2 Bortezomib/Dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial   2.  Developmental Therapeutics - TBD A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an Insulin Like Growth Factor-1 Receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors